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Recent advances in achieving highly durable clinical
responses via inhibition of immune checkpoint proteins
including CTLA-4 and PD1 have revolutionized the out-
look for cancer therapy. However, along with impressive
clinical activity (response rate of ~25% with either anti-
CTLA-4 or anti-PD1 as single agent, but > 50% with a
combination), severe immune-related adverse events
(irAEs) due to the breaking of immune self- tolerance (25-
30% with anti-CTLA-4 and up to 15-17% with anti-PD1)
are becoming increasingly evident. Sustained target inhibi-
tion as a result of a long half-life (>15-20 days) and >70%
target occupancy for months are likely contributing to
severe irAEs observed in the clinic with antibodies target-
ing immune checkpoint proteins. Our efforts are therefore
focused on developing immune checkpoint blockers with
potent anti-tumor activity but with a shorter pharmacoki-
netic profile as a strategy to better manage severe irAEs.
Flexibility in adjusting the drug exposure because of a
shorter t½ could also be advantageous for use in combina-
tion with other checkpoint modulators or anti-cancer
agents.
Peptide antagonist AUR-012, constructed with elements
from human PD-1, displayed equipotent antagonism
towards PD-L1 and PD-L2 with potent activity in rescue
of lymphocyte proliferation and effector functions. Rescue
of proliferation of immune cells analyzed upon stimulation
with anti-CD3/anti-CD-28 indicated a complete rescue of
CD4+ and CD8+ T cells. Interestingly, the proliferation of
CD4+, Foxp3+ T cells was completely abolished with
AUR-012 treatment indicating a complete suppression of
regulatory T cells. Sustained activation of circulatory
immune cells and their ability to secrete IFN-g up to 72 h
indicate that pharmacodynamic effects persist even after
the clearance of AUR-012 in animal models, thus support-
ing a dosing interval of up to 3 days. In models of mela-
noma, breast, kidney and colon cancers, AUR-012 showed
efficacy in inhibition of both primary tumor growth and
metastasis. Additionally, anti-tumor activity of AUR-012
in a pre-established CT26 model correlated well with
pharmacodynamic effects as indicated by intratumoral
recruitment of CD4+ and CD8+ T cells, and a reduction
in PD1+ T cells (both CD4+ & CD8+) in tumor and
blood. In 14-day repeated dose toxicity studies, AUR -012
was well tolerated at 100x of the efficacious doses.
These findings demonstrating equipotent antagonism
of both PD-L1 and PD-L2 signaling and the observed
correlation between anti-tumor activities with the mod-
ulation of specific T-cell populations support further
development of AUR-012 in the clinic.
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